Sign in
Taking people in United StatesEarly phase 1

18F-Fluciclovine PET/CT scans to find and study brain metastases

Tests 18F-Fluciclovine PET/CT imaging of brain metastases, before and after treatment.

Key facts

Who runs it
University of Arizona
Where
Tucson, United StatesSee the site
Trial code
Registry title
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
Status
Recruiting
Phase
Early phase 1
People taking part
20 people, planned
Started
10 Sept 2024
Planned end
31 Oct 2026
Type of study
Interventional
Treatments tested
  • 18F-Fluciclovine (Axumin) PET/CT
Record updated
21 September 2026

Who can take part

The trial is looking for adults with cancer that has spread, or may have spread, to the brain. They must be scheduled for brain surgery or radiation. They will have 18F-fluciclovine PET/CT scans.

Age
18 Years to 99 Years
Sex
All sexes
Disease stage
Brain metastases (cancer spread to the brain), suspected or diagnosed. A brain MRI in the past 2 months must show this spread. People must have a known history of cancer.
Earlier treatment
People must be scheduled for surgical resection, stereotactic radiosurgery or whole brain radiation therapy. The lesion(s) studied must not have had brain surgery or radiation before. Earlier local brain treatment is allowed if at least one studied lesion is outside the earlier treatment area (10% isodose line of prior RT).
Main reasons for not taking part
  • Brain biopsy of the studied lesion(s) less than 4 weeks before the PET/CT scan
  • Prior brain surgery or radiation of the studied lesion(s), or all studied lesions inside an earlier radiation area
  • Treatment of the studied lesion(s) or start of systemic therapy after the last MRI and before the PET/CT scan
  • Unable to lie still on the back for the scan
  • Joining the trial would delay care
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Patients with clinically suspected or diagnosed brain metastatic lesion(s)
  • Age ≥ 18 years
  • Known history cancer
  • Brain MRI in the past 2 months positive for metastatic disease
  • Scheduled for treatment: Surgical resection, or stereotactic radiosurgery, or whole brain radiation therapy
  • Can tolerate 18F-fluciclovine PET/CT exam (can lie still on their back for the duration of the scan)
  • Ability to understand and the willingness to sign a written informed consent

Who cannot take part

  • Patients who have had prior brain surgery or radiation treatment of the index lesion(s)
  • Patients who have had treatment of the index brain lesion(s) or initiation of systemic therapy after the last MRI and prior to the PET/CT scan
  • Prior history of localized brain treatment (surgery or stereotactic radiosurgery /fractionated stereotactic radiotherapy) allowed, if at least one index lesion is not adjacent to previous treatment (10% isodose line of prior RT). Patients with only index lesion(s) within 10% isodose line of prior treatment would be excluded. For example, if ALL index lesions are within the 2.2Gy isodose line of previously treated lesions to 22Gy in 1 fractions, the patient would be ineligible, however if there is 1 index lesion not in the prior radiation field, then that patient would be eligible but all other lesions in prior radiation fields would be excluded from analysis
  • Concurrent or prior enrollment on other clinical trials would not exclude patients, as long as all other eligibility criteria are met
  • Patients who do not meeting inclusion criteria
  • Patients who have had a brain biopsy of the index lesion(s) sooner than 4 weeks from the brain 18F-fluciclovine PET/CT (to minimize false positive uptake due to inflammation)
  • Inability to tolerate 18F-fluciclovine PET/CT exam
  • Enrollment delays patient care

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Brain metastases

This trial is currently available in United States.

  • Arizona Cancer Center at UMC North/University Medical CenterTucson, United StatesContact: Bital Savir-Baruch, MDTaking people

About the trial

What the trial wants to find out

The goal of this diagnostic intervention clinical trial is to compare 18F-Fluciclovine uptake within brain lesions over 60 minutes compared with standard of care positive histology confirmation or confirmation MRI images. The main questions it aims to answer are:

Read full original descriptionShow less

1. What are the dynamics of 18F-Fluciclovine update within a non-treated metastatic brain lesion over 60 minutes? 2. What are the dynamics of 18F-fluciclovine update within recently treated metastatic brain lesions? 3. What is the potential use of 18F-Fluciclovine in delineating true local progression from radionecrosis in patients with clinical uncertainty of indeterminate MRI?

Participants will undergo an 18F-fluciclovine head PET/CT scan prior to treatment for brain metastatic lesion(s). The study will characterize uptake dynamic PET images over 60 minutes. Uptake within the lesions and the benign brain parenchyma will be plotted on a time activity curve for 60 mins. Patients will undergo a second 18F-fluciclovine PET/CT to evaluate 18F-fluciclovine uptake in treated lesions over 60 minutes. This will be offered concurrently with the post-procedure standard of care (SOC) MRI to evaluate post-treatment changes. Uptake within the lesions and the benign brain parenchyma will be plotted on a 60 min time activity curve. Results will be compared to the pre-treatment baseline images. A third 18F-fluciclovine PET/CT will be offered to evaluate post radiation changes necrosis from recurrence, for up to 10 patients in our cohort who are under clinical surveillance (up to three years surveillance) and developed MRI evidence of either true progression or radionecrosis with clinical uncertainty after stereotactic radiosurgery. The initial 18F-fluciclovine PET/CT will serve as a baseline PET/CT scan. This will be compared to post procedural histological confirmation.

The group in the trial

  • 18F-Fluciclovine (Axumin) PET/CTTreatment being tested

    Patients with recently diagnosed brain metastatic lesion(s) will be recruited based on MRI with or without histological confirmation, per standard of care. All patients will undergo an 18F-fluciclovine head PET/CT scan prior to treatment for brain metastatic lesions, post treatment, and 3 years post treatment.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
Plain-language title
18F-Fluciclovine PET/CT scans to find and study brain metastasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06055790, who can take part
Record updated
21 September 2026